Bradley A. McGregor, MD

home / authors / bradley-a-mcgregor-md

Articles

Bradley McGregor, MD

Dr McGregor on the Clinical Implications of the DAD-IO Trial in Urothelial Carcinoma

Bradley A. McGregor, MD
August 20th 2024

Bradley McGregor, MD, discusses the clinical implications of the DAD-IO trial in patients with metastatic urothelial carcinoma.

Read More

Bradley McGregor, MD

Dr. McGregor Discusses Ongoing Trials in Non-Clear Cell RCC

Bradley A. McGregor, MD
October 11th 2021

Bradley McGregor, MD, discusses ongoing trials in patients with non-clear cell renal cell carcinoma (RCC).

Read More

Bradley McGregor, MD

Dr. McGregor on the Focus of Future Research Efforts in RCC

Bradley A. McGregor, MD
January 7th 2021

Bradley McGregor, MD, discusses the focus of future research efforts in renal cell carcinoma.

Read More

Dr. McGregor on Future Research in mCRPC

Dr. McGregor on Future Research in mCRPC

Bradley A. McGregor, MD
September 15th 2020

Bradley McGregor, MD, discusses future research in metastatic castration-resistant prostate cancer.

Read More

Dr. McGregor on the Evolving Treatment Landscape of RCC

Dr. McGregor on the Evolving Treatment Landscape of RCC

Bradley A. McGregor, MD
August 25th 2020

Bradley McGregor, MD, discusses the evolving treatment landscape of renal cell carcinoma.

Read More

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

Ziad Bakouny, MD, MSc;Bradley A. McGregor, MD;Toni K. Choueiri, MD
December 5th 2018

In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need